Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Regional Disparities in Cancer Survival in Iran: Insight From a National Surveillance of Cancer Survival in Iran (Irancansurv) Publisher Pubmed



Nemati S1 ; Saeedi E1, 2 ; Lotfi F1 ; Nahvijou A1 ; Pirnejad H3 ; Cheraghi M4 ; Rezaeianzadeh A5 ; Dolatkhah R6 ; Bazarafshan A7 ; Golpazir A8 ; Yaghoobiashrafi M9 ; Abdi S1 ; Alvand S10 ; Ravankhah Z11 Show All Authors
Authors
  1. Nemati S1
  2. Saeedi E1, 2
  3. Lotfi F1
  4. Nahvijou A1
  5. Pirnejad H3
  6. Cheraghi M4
  7. Rezaeianzadeh A5
  8. Dolatkhah R6
  9. Bazarafshan A7
  10. Golpazir A8
  11. Yaghoobiashrafi M9
  12. Abdi S1
  13. Alvand S10
  14. Ravankhah Z11
  15. Mohebbi E1, 12
  16. Khosravi A13
  17. Etemadi A14
  18. Sheikh M15
  19. Roshandel G16
  20. Ghanbarimotlagh A17
  21. Partovipour E18
  22. Najafi F19
  23. Malekzadeh R20
  24. Mohagheghi MA1
  25. Zendehdel K1

Source: Cancer Epidemiology Published:2023


Abstract

Background and objectives: We aimed to investigate geographical disparity in cancer survival in 9 provincial population-based cancer registries in Iran from 2015 to 2016. Material and method: In the current study, data from 90,862 adult patients (aged >15 years) diagnosed with cancer were retrieved from 9 population-based cancer registries across Iran. Five-year survival rates were estimated by applying relative survival approaches. We also applied the international cancer survival standard weights for age standardization. Finally, we calculated the excess hazard ratio (EHR) for each province adjusted for age, sex, and cancer sites to estimate the excess hazard ratio of mortality compared to the capital province (Tehran). Results: The largest gap in survival was observed in more curable cancer types, including melanoma (41.4%), ovary (32.3%), cervix (35.0%), prostate (26.7%), and rectum (21.4%), while the observed geographical disparity in lethal cancers such as lung, brain, stomach, and pancreas was less than 15%. Compared to Tehran, we found the highest excess hazard of death in Western Azerbaijan (EHR=1.60, 95% CI 1.51, 1.65), Kermanshah (EHR=1.52, 95% CI=1.44, 1.61), and Kerman (EHR=1.46, 95% CI=1.38, 1.53). The hazard ratio of death was almost identical in Isfahan (EHR=1.04, 95% CI=1.03, 1.06) and Tehran provinces. Conclusion: Provinces with higher HDI had better survival rates. IRANCANSURV study showed regional disparities in cancer survival in Iran. Cancer patients in provinces with a higher Human Development Index (HDI) had a higher survival rate and lived longer compared to the patients in provinces with medium and low HDI regions. © 2023 Elsevier Ltd
Related Docs
View other Related Docs
1. National Surveillance of Cancer Survival in Iran (Irancansurv): Analysis of Data of 15 Cancer Sites From Nine Population-Based Cancer Registries, International Journal of Cancer (2022)
2. Population-Based Cancer Survival in the Golestan Province in the Northeastern Part of Iran 2007–2012, Cancer Epidemiology (2022)
3. Risk of Second Primary Neoplasms Among Cancer Survivors: A Population-Based, Cohort Study in Golestan Province, Northern Iran, 2004–2019, Cancer Medicine (2025)
Experts (# of related papers)
View all Related Experts
Reza Malekzadeh (8)
Azin Nahvijou (5)
Other Related Docs
4. Iran National Cancer Control Program (Irnccp): Goals, Strategies, and Programs, Medical Journal of the Islamic Republic of Iran (2022)
5. Colorectal Cancer Incidence Trends in Golestan, Iran: An Age-Period-Cohort Analysis 2004–2018, Cancer Epidemiology (2023)
6. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 a Systematic Analysis for the Global Burden of Disease Study 2019, JAMA Oncology (2022)
7. National and Subnational Burden of Female and Male Breast Cancer and Risk Factors in Iran From 1990 to 2019: Results From the Global Burden of Disease Study 2019, Breast Cancer Research (2023)
8. The 15-Year National Trends of Endocrine Cancers Incidence Among Iranian Men and Women; 2005–2020, Scientific Reports (2023)
9. Continued Increase in Incidence of Kidney Cancer in Iran and Its 31 Provinces, International Journal of Cancer Management (2024)
10. Esophageal and Gastric Cancer Incidence Trends in Golestan, Iran: An Age-Period-Cohort Analysis 2004 to 2018, International Journal of Cancer (2023)
11. Population Attributable Proportion and Number of Cancer Cases Attributed to Potentially Modifiable Risk Factors in Iran in 2020, International Journal of Cancer (2023)
12. Trend of Breast Cancer Incidence in Iran During a Fifteen-Year Interval According to National Cancer Registry Reports, Iranian Journal of Breast Diseases (2022)
13. Trends in Incidence of Prostate Cancer in Iran and Its 31 Provinces During 2003 - 2016, International Journal of Cancer Management (2023)
14. Breast Cancer Incidence Trends in Golestan, Iran: An Age-Period-Cohort Analysis by Ethnic Region, 2004-2018, Cancer Epidemiology (2024)
15. Cancer Incidence in the East Azerbaijan Province of Iran in 2015-2016: Results of a Population-Based Cancer Registry, BMC Public Health (2018)
16. Investigating Socioeconomic Inequality in the Incidence of Breast Cancer in Iran: Interprovincial Analysis and Comparison, Scientific Journal of Kurdistan University of Medical Sciences (2025)
17. Mortality Rates and Years of Life Lost Due to Cancer in Iran: Analysis of Data From the National Death Registration System, 2016, International Journal of Cancer Management (2022)
18. Clinical Breast Cancer Registry of Ir. Iran (Cbcr-Ir): Study Protocol and First Results, Archives of Iranian Medicine (2023)
19. Incidence, Mortality, and Epidemiological Aspects of Cancers in Iran; Differences With the World Data, Journal of B.U.ON. (2016)
20. Relative Survival of Breast Cancer Patients in Iran, Asian Pacific Journal of Cancer Prevention (2015)